ALS TDI and to-BBB collaborate on potential treatments for Motor Neuron Disease
The blood-brain barrier (BBB) fortifies the walls of blood vessels to prevent the entry of certain toxic substances into the brain. While maintaining this crucial protection, the barrier also poses challenges to delivering potential therapeutics for neurodegenerative disorders such as ALS.
Under the terms of the agreement, ALS TDI will use to-BBB’s CNS-targeted liposomal drug delivery system, the G-Technology®, as a tool to enhance the transport of several different compounds to the brain across the blood-brain barrier. The Institute will screen compounds in a preclinical model of ALS to determine if the enhanced formulation of the proposed treatments have an improved effect on disease course.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.